Lymph nodes as a target for the use of dendritic cell vaccines: modern approaches and prospects
Open Access
- 9 September 2025
- journal article
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (3) , 63-76
Abstract
This article provides an overview of current approaches to cancer immunotherapy, with an emphasis on the role of dendritic cells (DCs), lymph nodes (LNs), and innovative methods of vaccine delivery. Immunotherapy using DC-based vaccines represents a promising direction, capable of stimulating a specific immune response against tumor cells and forming long-term immune memory. Tumor-draining lymph nodes (TDLNs) play a key role in immune activation, as they are the sites where dendritic cells present tumor antigens and activate T-cells. In cancer, unlike viral infections, CD8+ T-cell activation occurs in two stages, and the effectiveness of this process depends on signals from the tumor microenvironment, which explains why the immune response to cancer is often weak.The article also discusses modern strategies for delivering vaccines to lymph nodes, including the use of nanoparticles, bioorthogonal reactions, and photothermally induced materials. These approaches help overcome the "granularity paradox", associated with the need to balance vaccine size for LN penetration and uptake by immune cells. The prospects of adoptive cell therapy using T-cells from TDLNs, as well as the role of exosomes and whole-cell tumor antigens in the development of effective vaccines, are also considered. Combination strategies, such as the use of vaccines together with checkpoint inhibitors (e. g., anti-PD1), demonstrate potential for enhancing antitumor immunity.The further advancement of cancer immunotherapy requires the integration of new knowledge about the biology of dendritic cells, modern methods of cell engineering, and nanotechnology to create personalized and effective antitumor vaccines.Keywords
This publication has 51 references indexed in Scilit:
- Dendritic Cell‐Hitchhiking In Vivo for Vaccine Delivery to Lymph NodesAdvanced Science, 2024
- CCR7 Mediated Mimetic Dendritic Cell Vaccine Homing in Lymph Node for Head and Neck Squamous Cell Carcinoma TherapyAdvanced Science, 2023
- In Situ Tumor Vaccine for Lymph Nodes Delivery and Cancer Therapy Based on Small Size NanoadjuvantSmall, 2023
- A Biodegradable Antigen Nanocapsule Promotes Anti‐Tumor Immunity via the cGAS‐STING PathwayAdvanced Functional Materials, 2023
- Remodeling Tumor‐Associated Neutrophils to Enhance Dendritic Cell‐Based HCC Neoantigen Nano‐Vaccine EfficiencyAdvanced Science, 2022
- Bioinspired and Biomimetic Delivery Platforms for Cancer VaccinesAdvanced Materials, 2021
- Development of a Cancer Vaccine Using In Vivo Click‐Chemistry‐Mediated Active Lymph Node Accumulation for Improved ImmunotherapyAdvanced Materials, 2021
- Improving Cancer Immunotherapy Outcomes Using BiomaterialsAngewandte Chemie International Edition, 2020
- Prevalence of CD8+ cytotoxic lymphocytes in human neoplasmsCellular Oncology, 2020
- Tumor‐derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitroHepatology, 2016